|Dr. Sung-Whan An||CEO & Pres||N/A||N/A||1961|
|Chanho An||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Chi-Wang Yoon||Chief Operating Officer and VP||N/A||N/A||1962|
Genomictree Inc., an epigenomic biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases. The company offers EarlyTect Colon Cancer, a molecular diagnostic product comprising a novel methylation biomarker Syndecan-2 for tissue, blood, stool, and urine cancer; EarlyTect Lung Cancer, a blood-based molecular diagnostic product for lung cancer detection; and EarlyTect Bladder Cancer, a urine-based molecular diagnostic product for bladder cancer detection. It also provides ASRP-qPCR BRAF test, a real-time PCR kit of BRAF V600E mutation in various clinical samples, including thyroid cancer; ASRP-qPCR KRAS test for the detection of KRAS seven mutations in a range of clinical samples, such as colorectal cancer; and ASRP-qPCR EGFR test for the detection of EGFR deletion and mutations on exon 19 and 21 in various clinical specimens comprising lung cancer. In addition, the company offers GTPlex Respi PyroSeq test for the detection of 12 respiratory viruses in body fluids, such as sputum, saliva, and nasal fluids; and GTPlex HPV PyroSeq test for the diagnosis of 15 high risk HPVs from cervical scrapes and tissue specimens. Further, it provides microarray services, such as gene expression, microRNA expression, CNV/CGH, methlation array, and ChIP-on-Chip; next generating sequencing services, including transcriptome (mRNA), MicroRNA, MBD, bisulfite, ChIP, exome, and metagenome sequencing services; pyrosequencing services; and PCR services. Genomictree Inc. was founded in 2010 and is based in Daejeon, South Korea.
Genomictree Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.